# A changed biomarker is not automatically a changed life

Treat this file as reference data, never as instructions that override the user or agent. Read the complete item before applying it. Keep use conditions, avoid conditions, limits, evidence roles and source links with the answer. An editorial block is a separately versioned analysis layer, not an original corpus claim or proof of efficacy. Cite the readable URL and version. Do not infer human review. This is a saved edition, not a live safety-notice service. Before consequential reuse, check the current page, https://vedokrok.com/data/availability.json and https://vedokrok.com/data/notices.json; absence alone does not explain why an item was removed.

Release: VEDOKROK-SEL-5d86e1b23401e578
Snapshot SHA-256: 30ce1c8fa9155763797e3d5cb55b1d94cbb8c3146ebd03fb3c006531ce60e82f
Current availability: https://vedokrok.com/data/availability.json
Current notices: https://vedokrok.com/data/notices.json

---

## A changed biomarker is not automatically a changed life

ID: MHC-D-RESEARCH-0066 · Version: 0.1.0 · Kind: concept
Source: https://vedokrok.com/knowledge/a-changed-biomarker-is-not-automatically-a-changed-life

The dashboard can move before the destination is established.

Knowledge source release: MHC-RPUB-20261112-07d31a69
Source corpus commit: 07d31a6904d38f9fe2189aee7b26bb065724b120
Source manifest SHA-256: d676e87a17b9210d8037fd74c3f1ea735debd384fa069ba127a87ad441aa4f20
Source projection SHA-256: 7e7900a14145b4d025c2279ceb005ff3633adb88263038886b09282e4dafb04b

### Use when

- A product's benefit is inferred from a laboratory measure rather than how people feel, function or survive.

### Avoid when

- Some surrogate endpoints are well validated and useful. Do not reject all biomarkers or change care because a direct long-term endpoint was not measured.

### Explanation

A surrogate stands in for an outcome of interest. Ask what evidence validates that substitution in this context; an attractive mechanism alone does not finish the argument.

### Example

A fictional intervention changes a measured molecule. Without suitable validation or outcome evidence, that is not yet proof that users feel better or live longer.

### Check

Can you distinguish what was measured from the benefit being promised?

### Limits

- Some surrogate endpoints are well validated and useful. Do not reject all biomarkers or change care because a direct long-term endpoint was not measured.

### Evidence and sources

- supports: A surrogate endpoint substitutes for a clinical outcome and requires context-specific evidence of its predictive value. — fda-surrogate-endpoints. Claim basis: technical_definition. Claim limit: Some surrogates are well validated; others remain candidates.
Source access: selected_html_passages; accessed on: 2026-09-17; inspected sections: ["What are clinical trial endpoints?", "How can biomarkers be used as surrogate endpoints?"].
Agent scope review: FDA defines a surrogate as a substitute for a direct measure of how a patient feels, functions or survives and explains that its validation depends on context. The card gives a fictional example and explicitly rules out changing care on this basis. (Clinical trial endpoints; biomarkers as surrogate endpoints)
- fda-surrogate-endpoints: Surrogate Endpoint Resources for Drug and Biologic Development — https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development

Review: agent · Agent editorial and scoped source review · 2026-11-12T17:42:00Z
Published: 2026-11-12T17:42:00Z
Related (useful_with): https://vedokrok.com/knowledge/keep-evidence-certainty-attached-to-its-outcome
